Picture of SIGA Technologies logo

SIGA — SIGA Technologies Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Momentum

Relative Strength (%)
1m+11.45%
3m+93.35%
6m+105.85%
1yr+131.31%
Volume Change (%)
10d/3m-0.68%
Price vs... (%)
52w High-14.8%
50d MA+31.69%
200d MA+62.74%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)19.11
PEG Ratio (f)n/a
EPS Growth (f)-15.61%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value5.44
Price to Tang. Book5.47
Price to Free Cashflow12.51
Price to Sales6.55
EV to EBITDA8.43

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital50.56%
Return on Equity48.14%
Operating Margin64.31%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for SIGA

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of SIGA Technologies EPS forecast chart

Profile Summary

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. It uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
December 28th, 1995
Public Since
May 30th, 2011
No. of Shareholders
26
No. of Employees
39
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
72,406,667
Blurred out image of a map
Address
31 East 62Nd Street, NEW YORK, 10065
Web
https://www.siga.com/
Phone
+1 2126729100
Contact
Laine Yonker
Auditors
PricewaterhouseCoopers LLP

SIGA Share Price Performance

Upcoming Events for SIGA

Q2 2022 SIGA Technologies Inc Earnings Release

Q3 2022 SIGA Technologies Inc Earnings Release

Similar to SIGA

Picture of ADMA Biologics logo

ADMA Biologics

us flag iconNASDAQ Global Market

Picture of Aerie Pharmaceuticals logo

Aerie Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Alimera Sciences logo

Alimera Sciences

us flag iconNASDAQ Global Market

Picture of ANI Pharmaceuticals logo

ANI Pharmaceuticals

us flag iconNASDAQ Global Market

Picture of Aptorum logo

Aptorum

us flag iconNASDAQ Global Market

FAQ

Or unlock with your email

Or unlock with your email